18F-FDG PET/CT for first follow-up post chemotherapy in lymphoma: Is it mandatory to do whole body scan?
Journal Title: Journal of Cancer Research & Therapy - Year 2015, Vol 3, Issue 3
Abstract
Objective: To assess the feasibility of 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) scan limited to the original sites of lymphoma in 1st follow-up (F/U) post-chemotherapy to reduce patient’s radiation exposure and scan time. Patients and methods: FDG PET/CT scans of 100 lymphoma patients were reviewed and the sites of disease in pre-Chemotherapy and the 1st F/U post-chemotherapy scans were recorded. The supposed saved time from PET part of the scan and reduction in radiation dose from CT part if PET/CT scan limited to the original sites of lymphoma in 1st F/U post-chemotherapy scan is used, were calculated. Result: 45% of 1st F/U post-chemotherapy PET/CT scans showed no significant residual FDG-uptake indicating complete metabolic response. Significant residual FDG-uptake at known disease sites was seen in 55% of 1st F/U post-chemotherapy scans indicating residual disease. No lesions with significant FDG uptake in new sites were detected in the 1st F/U post-chemotherapy PET/CT indicating no unexpected sites of lymphoma. The supposed reduction in the mean scan time and radiation dose is 5.3 ± 1.47 minutes and 4.2 ± 1.2 mSv respectively if scan limited to the sites of known disease is used in 1st FU-P-CHT, without missing any significant findings. Conclusion: It is not mandatory to do WB 18F-FDG PET/CT scan in assessment of early response to chemotherapy in curable lymphoma and it may be sufficient to limit scans to the sites of known disease without missing any significant findings, resulting in significant reduction in total radiation dose and time saving.
Authors and Affiliations
Farghaly H, Nasr H, Qarni AA, Elhussein W
Keywords
Related Articles
- EP ID EP545094
- DOI 10.14312/2052-4994.2015-4
- Views 81
- Downloads 0
The first American cancer patient to receive dicycloplatin chemotherapy: A case report
Dicycloplatin (DCP), an effective platinum drug, was developed in China and approved by Chinese FDA in 2012. Its side effects are more bearable than those of cisplatin and carboplatin. The bladder cancer patient presente...
Cancer estimation of incidence and survival in Algeria 2014
Cancer is one of the major public health problems in Algeria. In the last 25 years, a significant increase in the incidence of the major types of cancers has been observed in both sexes. Moreover, the 5-year survival rat...
High grade endometrial cancer: A prospective cohort study of the outcome of 120 patients after primary surgery
Objective: The purpose of this study was to assess survival and recurrence site and rate in patients with histological high grade endometrial cancer (grade 3 endometrioid and non endometrioid carcinoma) treated with stag...
Newly isolated compounds from West African Sorghum bicolor leaf sheaths Jobelyn® show potential in cancer immunosurveillance
Jobelyn®, a West African pharmaceutical product derived from Sorghum bicolor leaf sheaths has been shown to possess strong anti-tumour and anti-inflammatory properties. This study aims to evaluate the expression of cell...
A single center series highlights on incidence and management of gastric neuroendocrine tumours with literature review
Neuroendocrine tumours of the digestive system (GEP-NET) are relatively rare. Nevertheless, their diagnoses is rising as seen from studies in the US and elsewhere. Gastric neuroendocrine tumours (Gastric NETs) vary throu...